SAN DIEGO, Aug. 13, 2019 /PRNewswire/ -- GraphPad

RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2019 /PRNewswire/ -- AskBio, the world's foremost clinical stage and gene therapy platform company, has acquired

SUZHOU, China, Aug. 13, 2019 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616) today announces the dosing of the first patient in China for the Phase I registrational study of BLU-667, which was discovered by the company's partner Blueprint Medicines. This clinical trial is a part of the ongoing, global Phase I ARROW trial tha

TEGUCIGALPA, Honduras, Aug. 12, 2019 /PRNewswire/ -- The government of the Republic of Honduras announced to the national and international community: Honduras President, Juan Orlando Hernández, and members of his cabinet will travel to Washington DC, to participa

BRENTWOOD, Tenn., Aug. 12, 2019 /PRNewswire/ -- AAC Holdings, Inc. (NYSE: AAC) (the "Company") announced preliminary estimated operational and financial results for the second quarter ended June 30, 2019. Second Quarter 2019 Highlights: (All comparisons are to first quarter ended March 31, 2019, unless ot

ARLINGTON, Va., Aug. 12, 2019 /PRNewswire/ -- March of Dimes released the following statement from Stacey D. Stewart, President and CEO, in response to the Administration's action today finalizing the rule on the circumstances under which immigrants could be considered a "public charge," thereby endangering their immigration status. Ma

NEW YORK, Aug. 12, 2019 /PRNewswire/ -- Integrated Care Physicians, Inc. ("ICP" or the "Company"), a provider of Emergency Medicine and Acute Care management services and a BelHealth Investment Partners ("BelHealth") portfolio company, announced that Dr. Terry Meadows has joined the Company as Executive Chairman and Board Member.

BETHESDA, Md., Aug. 12, 2019 /PRNewswire/ -- The 2019 Community Health Institute (CHI) and EXPO, hosted by the National Association of Community Health Centers (

MARLBOROUGH, Mass., Aug. 12, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA®) therapeutic platform, today reported its financial results for the second quarter ended June 30,

SOUTH SAN FRANCISCO, Calif., Aug. 12, 2019 /PRNewswire/ -- Portola Pharmaceuticals, Inc.® (Nasdaq: PTLA)  today announced plans to offer, subject to market and other conditions, $200 million of its common stock in an underwritten public offering. The company expects to grant the underwriters a 30-day option to purcha